Checkpoint inhibitors Appear Effective in Stem Cell Transplant Recipients
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant […] The post Checkpoint inhibitors Appear...
View ArticleNovel Agent may Reverse Resistance to Targeted Therapy in Acute Leukemia and MDS
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have […] The post Novel Agent may Reverse Resistance to...
View ArticleFDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed...
CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment […] The post FDA Grants Accelerated Approval to...
View ArticleU.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute...
CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for […] The post U.S. FDA Approves Trisenox®...
View ArticleCRISPR Enhances Cancer Immunotherapy
Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved […] The post CRISPR Enhances Cancer Immunotherapy appeared first on .
View ArticleVenclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic...
CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared […] The post Venclexta Significantly Reduces...
View ArticleQuizartinib Improves Survival in Select Patients with Relapsed/Refractory...
According to the drug developer the novel precision cancer medicine, quizartinib improves the survival of individuals with relapsed/refractory acute myeloid […] The post Quizartinib Improves Survival...
View ArticleFDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma...
The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small […] The post FDA Approves Venetoclax for Chronic and...
View ArticleTibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia...
Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients […] The post Tibsovo Approved for Treatment of Relapsed/Refractory...
View ArticleVenclexta® Promising in Newly Diagnosed Acute Myeloid Leukemia
A supplemental New Drug Application (sNDA) has been filed with the U.S. Food and Drug Administration (FDA) for Venclexta® (venetoclax) […] The post Venclexta® Promising in Newly Diagnosed Acute Myeloid...
View Article
